CliffBio
biologic

Pavblu

aflibercept-ayyh

Loss of exclusivity—loss of exclusivity
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand namePavblu
Active ingredientaflibercept-ayyh
Strength2MG/0.05ML
Dosage formInjection
RouteIntravitreal
ModalityBiologic
FDA approvalAugust 2024
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Pavblu patent cliff — loss of exclusivity — | CliffBio